These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

357 related items for PubMed ID: 23593777

  • 1. Systemic immunoglobulin light-chain amyloidosis (AL) in Mexico: a single institution, 30-year experience.
    Hernández-Reyes J, Galo-Hooker E, Ruiz-Delgado GJ, Ruiz-Argüelles GJ.
    Rev Invest Clin; 2012; 64(6 Pt 2):604-8. PubMed ID: 23593777
    [Abstract] [Full Text] [Related]

  • 2. Induction bortezomib in Al amyloidosis followed by high dose melphalan and autologous stem cell transplantation: a single institution retrospective study.
    Scott EC, Heitner SB, Dibb W, Meyers G, Smith SD, Abar F, Kovacsovics T, Perez-Avraham G, Stentz A, Frires R, Dibb J, Maziarz RT.
    Clin Lymphoma Myeloma Leuk; 2014 Oct; 14(5):424-430.e1. PubMed ID: 24650974
    [Abstract] [Full Text] [Related]

  • 3. [Complete remission of nephrotic syndrome and improvement of renal function in a patient with light chain deposition disease following high dose chemotherapy with transplantation of autologous haematopoietic stem cells. A case study and review of literature].
    Adam Z, Krejcí M, Pour L, Stepánková S, Cermáková Z, Voska L, Teplan V, Krivanová A, Hájek R, Mayer J.
    Vnitr Lek; 2009 Nov; 55(11):1089-96. PubMed ID: 20017442
    [Abstract] [Full Text] [Related]

  • 4. Combined use of bortezomib, cyclophosphamide, and dexamethasone induces favorable hematological and organ responses in Japanese patients with amyloid light-chain amyloidosis: a single-institution retrospective study.
    Kikukawa Y, Yuki H, Hirata S, Ide K, Nakata H, Miyakawa T, Matsuno N, Nosaka K, Yonemura Y, Kawaguchi T, Hata H, Mitsuya H, Okuno Y.
    Int J Hematol; 2015 Feb; 101(2):133-9. PubMed ID: 25430082
    [Abstract] [Full Text] [Related]

  • 5. [Outcomes of AL-amyloidosis treatment with bortezomib, dexamethasone and cyclophosphamide or doxorubicin-containing regimens].
    Adam Z, Stork M, Pour L, Krejčí M, Zahradová L, Sandecká V, Hájek R, Cermáková Z, Pospíšilová Y, Navrátil M, Král Z, Mayer J.
    Vnitr Lek; 2012 Dec; 58(12):896-903. PubMed ID: 23427947
    [Abstract] [Full Text] [Related]

  • 6. High-dose melphalan with autologous stem cell transplantation after VAD induction chemotherapy for treatment of amyloid light chain amyloidosis: a single centre prospective phase II study.
    Perz JB, Schonland SO, Hundemer M, Kristen AV, Dengler TJ, Zeier M, Linke RP, Ho AD, Goldschmidt H.
    Br J Haematol; 2004 Dec; 127(5):543-51. PubMed ID: 15566357
    [Abstract] [Full Text] [Related]

  • 7. Immunoglobulin light chain amyloidosis: 2014 update on diagnosis, prognosis, and treatment.
    Gertz MA.
    Am J Hematol; 2014 Dec; 89(12):1132-40. PubMed ID: 25407896
    [Abstract] [Full Text] [Related]

  • 8. Bortezomib, thalidomide, and dexamethasone as induction therapy for patients with symptomatic multiple myeloma: a retrospective study.
    Kaufman JL, Nooka A, Vrana M, Gleason C, Heffner LT, Lonial S.
    Cancer; 2010 Jul 01; 116(13):3143-51. PubMed ID: 20564642
    [Abstract] [Full Text] [Related]

  • 9. High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis.
    Jaccard A, Moreau P, Leblond V, Leleu X, Benboubker L, Hermine O, Recher C, Asli B, Lioure B, Royer B, Jardin F, Bridoux F, Grosbois B, Jaubert J, Piette JC, Ronco P, Quet F, Cogne M, Fermand JP, Myélome Autogreffe (MAG) and Intergroupe Francophone du Myélome (IFM) Intergroup.
    N Engl J Med; 2007 Sep 13; 357(11):1083-93. PubMed ID: 17855669
    [Abstract] [Full Text] [Related]

  • 10. [More than 10 years of complete remission of monoclonal gammopathy of undetermined significance and cessation of light chain deposition disease-associated nephrotic syndrome following treatment with vincristine, adriamycin and high-dose dexamethasone (VAD)].
    Adam Z, Nedbálková M, Krejcí M, Pour L, Husek K, Veselý K, Cermáková Z, Krivanová A, Mayer J, Hájek R.
    Vnitr Lek; 2010 Mar 13; 56(3):240-6. PubMed ID: 20394211
    [Abstract] [Full Text] [Related]

  • 11. [Monoclonal gammopathy of undetermined significance (MGUS) in Mexican mestizos: one institution's experience].
    Ruiz-Delgado GJ, Gómez Rangel JD.
    Gac Med Mex; 2004 Mar 13; 140(4):375-9. PubMed ID: 15456147
    [Abstract] [Full Text] [Related]

  • 12. An overview of the use of high-dose melphalan with autologous stem cell transplantation for the treatment of AL amyloidosis.
    Sanchorawala V, Wright DG, Seldin DC, Dember LM, Finn K, Falk RH, Berk J, Quillen K, Skinner M.
    Bone Marrow Transplant; 2001 Oct 13; 28(7):637-42. PubMed ID: 11704785
    [Abstract] [Full Text] [Related]

  • 13. Secondary monoclonal gammopathy of undetermined significance is frequently associated with high response rate and superior survival in patients with plasma cell dyscrasias.
    Zou D, An G, Zhu G, Wang J, Shi L, Meng H, Xu Y, Sui W, Deng S, Zhan F, Qiu L.
    Biol Blood Marrow Transplant; 2014 Mar 13; 20(3):319-25. PubMed ID: 24296491
    [Abstract] [Full Text] [Related]

  • 14. Treatment of multiple myeloma.
    San Miguel JF, Bladé Creixenti J, García-Sanz R.
    Haematologica; 1999 Jan 13; 84(1):36-58. PubMed ID: 10091392
    [Abstract] [Full Text] [Related]

  • 15. [Renal disorders associated with monoclonal gammopathies: diagnostic and therapeutic progress].
    Bridoux F, Delbes S, Sirac C, Pourreau F, Puyade M, Desport E, Jaccard A, Fermand JP, Touchard G.
    Presse Med; 2012 Mar 13; 41(3 Pt 1):276-89. PubMed ID: 22244725
    [Abstract] [Full Text] [Related]

  • 16. [Renal disease in multiple myeloma].
    Hiromura K, Nojima Y.
    Nihon Rinsho; 2007 Dec 13; 65(12):2229-34. PubMed ID: 18069265
    [Abstract] [Full Text] [Related]

  • 17. Treatment of multiple myeloma: 2009 update.
    Prescrire Int; 2009 Dec 13; 18(104):263-6. PubMed ID: 20025098
    [Abstract] [Full Text] [Related]

  • 18. Bortezomib as induction before autologous transplantation, followed by lenalidomide as consolidation-maintenance in untreated multiple myeloma patients.
    Palumbo A, Gay F, Falco P, Crippa C, Montefusco V, Patriarca F, Rossini F, Caltagirone S, Benevolo G, Pescosta N, Guglielmelli T, Bringhen S, Offidani M, Giuliani N, Petrucci MT, Musto P, Liberati AM, Rossi G, Corradini P, Boccadoro M.
    J Clin Oncol; 2010 Feb 10; 28(5):800-7. PubMed ID: 20048187
    [Abstract] [Full Text] [Related]

  • 19. Intravenous melphalan, thalidomide and prednisone in refractory and relapsed multiple myeloma.
    Palumbo A, Avonto I, Bruno B, Ambrosini MT, Bringhen S, Cavallo F, Falco P, Boccadoro M.
    Eur J Haematol; 2006 Apr 10; 76(4):273-7. PubMed ID: 16519697
    [Abstract] [Full Text] [Related]

  • 20. [IgM-lambda multiple myeloma presenting with systemic amyloidosis].
    Higeta D, Yokohama A, Osaki Y, Tahara K, Mawatari M, Sekigami T, Koiso H, Saito T, Uchiumi H, Handa H, Karasawa M, Murakami H, Hirato J, Tsukamoto N, Nojima Y.
    Rinsho Ketsueki; 2009 Dec 10; 50(12):1711-4. PubMed ID: 20068279
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.